Targeting the cross-linking of collagen is an attractive therapeutic angle for patients with fibrosis, and indeed, agents blocking LOXL2 are now entering clinical trials in patients with IPF. This evidence concerns the gene LOXL2 and idiopathic pulmonary fibrosis.